ReviewThe New Oral Anticoagulants in Clinical Practice
Section snippets
Dabigatran
Dabigatran etexilate (Pradaxa) is the first oral direct thrombin inhibitor to be approved by the US Food and Drug Administration (FDA).
Rivaroxaban
Rivaroxaban (Xarelto) is the first oral direct coagulation factor Xa inhibitor approved for clinical use in the United States.
Apixaban
Apixaban (Eliquis) is an oral direct coagulation factor Xa inhibitor approved for clinical use in the United States.
Drug Interactions With NOAs
The NOAs have a low potential for drug interactions. Dabigatran etexilate, the prodrug, is a substrate of the P-glycoprotein (P-gp) efflux transporter. Hence, its plasma concentration increases with strong P-gp inhibitors (amiodarone, verapamil, clarithromycin, and ketoconazole) and reduces with potent P-gp inducers (rifampicin, carbamazepine, or phenytoin)35, 36; although no significant influence on its efficacy or safety has been reported, dosage adjustment may be needed.37 No dabigatran dose
Laboratory Testing and Monitoring for the NOAs
Given their rapid onset of action, stable pharmacokinetic properties, and lack of significant drug interactions, the NOAs do not require coagulation monitoring. However, overdoses, emergency perioperative settings, and bleeding events may warrant an assessment of the degree of anticoagulation. Table 5 summarizes the effects of the NOAs and warfarin on various coagulation parameters.
Prothrombin time (PT) is relatively insensitive at therapeutic levels of dabigatran compared with rivaroxaban and
Switching Therapies
Safely switching patients between anticoagulants is a frequent task faced by clinicians managing their patients’ anticoagulation needs. Suggested approaches are summarized in Table 6.39, 40, 50 The underlying factor that determines this approach is mainly based on accurate assessment of renal function.
Perioperative Management
Perioperative management of the NOAs is based on the urgency of the procedure, level of bleeding risk, and current renal function.39, 40, 50 The decision to stop treatment in nonurgent or elective surgery should depend on the risk of bleeding vs thrombosis.
Acute Stroke Requiring Thrombolytics
The safety of administration of thrombolytics in patients receiving concurrent NOAs is not established and poses a very high risk of bleeding. Anecdotal reports have documented the successful use of thrombolytics in patients taking dabigatran who were at least 7 hours past their last dose.51, 52 Similar reports with rivaroxaban and apixaban are lacking.
Cardioversion
For patients with AF of more than 48 hours' duration, therapeutic anticoagulation for at least 3 weeks before and 4 weeks after cardioversion is
Management of Bleeding Complications/Overdose
Lack of specific agents that reverse the anticoagulant effect complicates the management of NOA-associated bleeding events or the periprocedural reversal of anticoagulation. Management of minor bleeding, eg, epistaxis, consists of addressing the potential anatomical defects, eg, cauterization or nasal packing. The decision to hold the next dose of drug will hinge on the comorbidities and assessment of risks of drug discontinuation. Given the relatively short half-lives of the NOAs in patients
Choosing an Oral Anticoagulant
When identifying a long-term oral anticoagulant for a patient, it is important to adopt a personalized approach.68 The NOAs are not all superior in terms of efficacy compared with warfarin; hence, patients who are stable with warfarin therapy with acceptable/minimal complications will not benefit from switching to an NOA. Warfarin remains the standard of care for the management of patients with valvular AF or mechanical heart valves until further safety and efficacy data regarding the use of
Conclusion
The advent of NOAs represents a major development in the field of medicine. After more than half a century in which warfarin was the only oral anticoagulant available, the discovery of these agents has provided us with more options. Several more oral anticoagulants are in the development pipeline (Supplemental Table; available online at http://www.mayoclinicproceedings.org), and their use will only increase in the years to come. As we accumulate more experience with these agents, we will need
References (68)
- et al.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
Lancet
(2010) - et al.
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
J Thromb Haemost
(2007) - et al.
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Lancet
(2007) - et al.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet
(2008) - et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Lancet
(2009) - et al.
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Lancet
(2010) - et al.
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
J Thromb Haemost
(2011) - et al.
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
J Thromb Haemost
(2011) - et al.
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
Blood
(2012) - et al.
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
J Am Coll Cardiol
(2011)
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies
Blood
HIT: treatment easier, prevention harder
Blood
Removal of dabigatran by hemodialysis
Am J Kidney Dis
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis
CMAJ
Reviewing the reality: why we need to change
Eur Heart J Suppl
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Br J Clin Pharmacol
Dabigatran versus warfarin in patients with atrial fibrillation
N Engl J Med
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
N Engl J Med
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
J Arthroplast
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, non-inferiority trial
Thromb Haemost
Pradaxa
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials
Arch Intern Med
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial
Circulation
Pharmacodynamic and pharmacokinetic basics of rivaroxaban
Fundam Clin Pharmacol
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
N Engl J Med
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
N Engl J Med
Oral rivaroxaban for symptomatic venous thromboembolism
N Engl J Med
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
N Engl J Med
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
N Engl J Med
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Eur Heart J
Xarelto [package insert]
Cited by (82)
Supportive care in multiple myeloma: Current practices and advances
2021, Cancer Treatment and Research CommunicationsCitation Excerpt :Recently, a novel risk prediction tool known as the IMPEDE-VTE was developed for identifying MM patients at high risk for getting a VTE that accounts for race, treatments used (IMiDs, dexamethasone and doxorubicin), BMI, pelvic/hip fractures, history of prior VTE, presence of central venous catheter, use of erythropoiesis-stimulating agents and existing use of anticoagulation [55,56]. One of the recent advances in anticoagulation have been the introduction of the direct oral anticoagulants (DOACs) [57]. This has provided an oral option with minimal drug and food interactions and no need for monitoring levels as in the use of warfarin.
Direct-acting Oral Anticoagulants in Dermatologic Surgery
2020, Actas Dermo-SifiliograficasA novel fibrinolytic serine metalloprotease from the marine Serratia marcescens subsp. sakuensis: Purification and characterization
2018, International Journal of Biological MacromoleculesPharmacologic interactions
2018, Cardiac Intensive CareMonitoring of warfarin therapy: Preliminary results from a longitudinal pilot study
2018, Microchemical JournalCitation Excerpt :Compared to WAR, DOACs have a more rapid onset of action (time to peak concentration: 2–4 h instead of 72–96 h) and shorter half-lives (5–17 h instead of 40 h). Moreover, they are administered at fixed doses, and do not require a routine coagulation monitoring [12–15]. Nevertheless, the new anticoagulant drugs also have drawbacks: a) they are more expensive compared to the traditional vitamin K antagonists, b) patients quickly lose the anticoagulant effect and are unprotected from thrombosis if a single DOACs dose is missed, c) specific antidote (i.e. Idarucizumab) is currently available only for Dabigatran and d) DOACs are unsuitable for treating patients with mechanical heart valves.